Our Leadership Team

Paul Sekhri has over 35 years of experience in the Life Science Industry. His experience encompasses senior management in large corporate pharmaceutical and biotechnology companies, as well as private equity and venture capital. Mr. Sekhri is currently Chairman, President and Chief Executive Officer of vTv Therapeutics, Inc. From 2019 until 2022, he was President and CEO of eGenesis, Inc.. From 2015 until 2018 Mr. Sekhri served as President and CEO of Lycera Corp.. Prior to this, he served as Senior Vice President, Integrated Care for Sanofi from April 2014 through January2015. Previously, he served as Group Executive Vice President, Global Business Development and Chief Strategy Officer for Teva Pharmaceutical Industries, Ltd. Prior to joining Teva, he spent five years as Operating Partner and Head of the Biotechnology Operating Group at TPG Biotech, the life sciences venture capital arm of TPG Capital. From 2004-2009, Mr. Sekhri was Founder, President, and Chief Executive Officer of Cerimon Pharmaceuticals, Inc. Prior to founding Cerimon, Mr. Sekhri was President and Chief Business Officer of ARIAD Pharmaceuticals, Inc. Previously, Mr. Sekhri spent five years at Novartis as Senior Vice President, and Head of Global Search and Evaluation, Business Development and Licensing for Novartis Pharma AG.

Mr. Sekhri has been a director on more than 35 private, public company, and non-profit Boards, and is currently a member of the Board of Directors of AdhereTech, Likeminds, Spring Discovery, and Veeva Systems Inc. Mr. Sekhri is also the Chairman of the Boards of Directors of Compugen Ltd., Longboard Pharmaceuticals, Resolution Therapeutics, and Kaerus Bioscience. Additionally, he is on the Board of Directors of The Metropolitan Opera, the Advisory Council of the New York Philharmonic, and is the newly named Chairman of Young Concert Artists, Inc. He also serves as a Trustee of The English Concert in America.

Dr. Tung brings more than 20 years of financial management, investment experience, and strategic leadership for both private and public companies in the life sciences industry.

Prior to joining the Company, Dr. Tung was the chief financial officer of AdvanCell Pty Limited, an Australian clinical-stage radiopharmaceutical company from August 2023 to January 2025.

From April 2020 until July 2023, Dr. Tung held the position of vice president-corporate strategy/investor relations with FibroGen Inc., a publicly traded biopharmaceutical company.

From July 2016 to September 2019 he held the position of senior vice president-corporate strategy/investor relations at Aclaris Therapeutics, Inc., a publicly traded biopharmaceutical company. Before joining Aclaris, he led the portfolio construction and risk management of healthcare-dedicated funds as a portfolio manager at several firms. Dr. Tung earned B.A. and B.S. degrees in economics and biology, respectively, from The George Washington University, and a combined M.D./MBA from Tufts University School of Medicine.

He is a licensed physician in the states of Massachusetts and New York.

Thomas Strack, M.D., has 30 years of biopharmaceutical industry experience and has led all phases of clinical development from phase 1 to phase 3, NDA and commercialization. Dr. Strack previously served as CMO at Faeth Therapeutics (2022) where he was responsible for first-in-human trials of targeted nutritional and metabolic interventions in cancer patients. Prior to his role at Faeth Therapeutics, Dr. Strack served as SVP Clinical Development at Molecular Templates (2019-2022), following his position as VP Clinical Development at Progenics (2015-2018), where he was responsible for the pivotal studies leading to the approval of Azedra®, a treatment of patients with malignant pheochromocytoma, and Pylarify®, a targeted imaging agent for patients with metastatic prostate cancer. At Asubio (2012-2015), Dr. Strack served as R&D Head, where he was responsible for first-in-human trials targeting CNS diseases, amongst others. At Takeda (2009-2012), as VP Metabolic Diseases, he was responsible for portfolio strategy and partnerships, and the approval of Nesina®, an oral diabetes medication. Dr. Strack served as Sr. Medical Director at Pfizer (2000-2008), where he was responsible for late stage clinical development and medical affairs of various endocrine treatments, such as Exubera®, and ophthalmological and oncologic assets. As Senior Scientist at Eli Lilly and Company (1993-2000), he was involved in the clinical development of various endocrine/metabolic and oncologic assets from first-in-human to pivotal and post-marketing trials. He also served in regulatory affairs, oncology products.

Dr. Strack began his pharmaceutical industry career at Eli Lilly Canada in 1993. He earned his MD and Doctorate from the Johannes Gutenberg University in Mainz, Germany, where he also completed his internal medicine and endocrinology residencies, wi

Carmen has more than 30 years of pharmaceutical research and development experience focused on the metabolic space. She has been instrumental in taking TTP399, our Glucokinase Activator program from idea to clinical development. Carmen was a member of the vTv IPO team, having joined the company as a result of vTv’s former partnership with Novo Nordisk. During her career, Carmen has managed more than 12 INDs and has run numerous positive clinical studies in the field of diabetes. Carmen is an inventor on more than 20 patents and patent applications and an author on numerous peer-reviewed scientific publications. Carmen obtained her Ph.D. at the Universidad Autonoma de Madrid, Spain, in the field of metabolic diseases and mitochondrial development.